In particular, the group of Villagra highlighted the role of HDAC6 in PD-L1 modulation in a melanoma cells line and reported that Nexturastat, a selective HDAC6i, counteracted the IFN-γ induced up-regulation of PD-L1 on tumor cells, thus increasing the antitumor immune response of anti PD-L1 treatment (19). Here, IFNG is linked to neoplasm.